Published on: Thu, Aug 01 2013
A newly-released report from Pharmaceutical Research and Manufacturers of America (PhRMA) has revealed that nearly 450 new medicines are in development to treat neurological disorders, including 28 for epilepsy and seizures.
"The Epilepsy Foundation applauds PhRMA and its member companies for their research investments and commitments to innovation," said Phil Gattone, President & CEO of the Epilepsy Foundation. "For the one third of people with epilepsy who have no effective treatment options to those seeking better seizure control and fewer side effects, investments in new options is critical. Our community welcomes the news of the Neurological Disorders report and the hope it brings for the future in epilepsy care."
Of the 28 epilepsy medicines listed in the report, seven are in or have completed phase one of development; eight are in or have completed phase two; and, thirteen are in or have completed phase three.
Epilepsy and seizures not only cost families opportunities to spend time together and for children to miss school, but they also affect the U.S. economy due to billions of dollars in health care costs and lost wages.
The Epilepsy Foundation fully supports and thanks PhRMA and its member companies for accelerating access to new therapies for all those impacted by epilepsy.
To read the full report, visit PHRMA.org.